Intravenous Iron Injection in Cancer Patients With Anemia
Intravenous Iron Injection in Cancer Patients With Anemia
-  Multifactorial pathogenesis is involved in anemia of cancer patients and defining the
 causes of anemia is not always simple.

 -  Currently, treatment options available for anemia in cancer patients include red blood
 cell (RBC) transfusion, erythropoietin stimulating agent (ESA), and iron
 supplementation, accompanying considerable pros and cons for each treatment.

 -  Previous studies have demonstrated benefit when treating with IV iron in combination
 with ESA and, more recently, evidence is emerging to suggest a role for IV iron alone.

 -  In this study, investigator will assess the efficacy of intravenous iron for the
 treatment of anemia in cancer patients.

 -  Improvement of anemia and the improvement of quality of life compared to conservative
 treatment of intravenous iron
This study is a comparative clinical trial of prospective, multicenter, randomized trials to
 evaluate the efficacy of intravenous iron (Ferinject®) in cancer patients with anemia.

 Changes in hemoglobin in the treated and conservative treatment groups with a single
 intravenous Ferrinject® in patients with anemia by chemotherapy are identified.

 1. Clinical Drug Ferinject Injection For patients undergoing chemotherapy, ferinject 1000mg
 will be injected within 24 hours or 24 hours after day 1 of the next chemotherapy cycle.

 Patients using targeted therapies can be dosed at any time after recognizing Hb
 8.0-10.5g / dL and injecting 1000 mg of ferinject.

 -  The administration of ferinject is a single dose, no re-administration. If
 chemotherapy is not performed, it can be administered at any time if the selection
 and exclusion criteria are met.

 -  The administration period for ferinject should be administered within 24 hours or
 24 hours after the day 1 of the chemotherapy cycle based on the results of phase 2
 studies

 2. remedies Within the period of sample collection of visits 2 to 4 after study enrollment,
 if the physician determines that treatment for clinically meaningful anemia is
 necessary, treatment for anemia other than ferinjects will be followed. Treatment for
 anemia will include remedies such as iron (oral or intravenous), hematopoietic
 accelerators, and blood transfusions, and will be determined by researchers at each
 institution to provide optimal treatment for patients. At the time this treatment is
 administered, the subject will be dropped from the clinical trial.
Inclusion Criteria:

 The subject should be diagnosed with solid cancer or lymphoma. Hemoglobin level of test
 subject should be in the range of 8.0-10.5g / dL, or he / she has experienced hemoglobin
 reduction of 2g / dL or more during chemotherapy.

 Exclusion Criteria:

 The patients have a history of iron (oral or intravenous), hematopoietic stimulating agents
 (ESA), and dialysis within 4 weeks of study enrollment.

 There is evidence that the patient's disease is a bone marrow invasion. There is a
 hypersensitivity reaction to ferinject or the components of ferinject.